Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer
Authors
Keywords
-
Journal
IMMUNOLOGICAL REVIEWS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-08-07
DOI
10.1111/imr.13255
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer
- (2023) Martin J. Raftery et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
- (2023) D. Nixdorf et al. LEUKEMIA
- Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy
- (2023) Muhammad Naeem et al. LIFE SCIENCES
- A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7
- (2023) Mansour Poorebrahim et al. CANCER LETTERS
- Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
- (2022) Louai Labanieh et al. CELL
- Modular design of synthetic receptors for programmed gene regulation in cell therapies
- (2022) Iowis Zhu et al. CELL
- Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
- (2022) Gils Roex et al. Journal of Translational Medicine
- Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion
- (2022) Michael L. Olson et al. LEUKEMIA
- NK-92 cells retain vitality and functionality when grown in standard cell culture conditions
- (2022) Rebecca Kotzur et al. PLoS One
- Next-Generation CAR T-cell Therapies
- (2022) Regina M. Young et al. Cancer Discovery
- Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
- (2022) Emmanuel Donnadieu et al. Journal for ImmunoTherapy of Cancer
- T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion
- (2022) Laura T Morton et al. Journal for ImmunoTherapy of Cancer
- Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia
- (2022) Frank Cichocki et al. BLOOD
- The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose
- (2022) David Luque-Paz et al. Expert Review of Anti-Infective Therapy
- Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.
- (2022) Niels W.C.J. van de Donk et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
- (2022) Xi Wu et al. Journal of Hematology & Oncology
- ROR1-targeting switchable CAR-T cells for cancer therapy
- (2022) Haiyong Peng et al. ONCOGENE
- DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study
- (2022) Chiara Focaccetti et al. Frontiers in Immunology
- Clonal expansion and epigenetic inheritance of long-lasting NK cell memory
- (2022) Timo Rückert et al. NATURE IMMUNOLOGY
- KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
- (2022) Ye Li et al. NATURE MEDICINE
- Engineered and Banked iPSCs for advanced NK and T cell immunotherapies
- (2022) Frank Cichocki et al. BLOOD
- Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future
- (2022) Allison Betof Warner et al. CLINICAL CANCER RESEARCH
- Synthetic cytokine circuits that drive T cells into immune-excluded tumors
- (2022) Greg M. Allen et al. SCIENCE
- Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
- (2022) Frank Cichocki et al. Nature Communications
- Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes
- (2021) Emiliano Roselli et al. JOURNAL OF CLINICAL INVESTIGATION
- NK cell-based cancer immunotherapy: from basic biology to clinical development
- (2021) Sizhe Liu et al. Journal of Hematology & Oncology
- Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
- (2021) Max Jan et al. Science Translational Medicine
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural Killer Cells: From Innate to Adaptive Features
- (2021) Adriana M. Mujal et al. Annual Review of Immunology
- Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
- (2021) Christine Ambrose et al. PLoS One
- SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models
- (2021) Axel Hyrenius-Wittsten et al. Science Translational Medicine
- SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma
- (2021) Joseph H. Choe et al. Science Translational Medicine
- CAR-T cell therapy: current limitations and potential strategies
- (2021) Robert C. Sterner et al. Blood Cancer Journal
- T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
- (2021) Apostolia-Maria Tsimberidou et al. Journal of Hematology & Oncology
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- (2021) Bijal D Shah et al. LANCET
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
- (2021) Jay Y. Spiegel et al. NATURE MEDICINE
- NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
- (2021) Alejandra Leivas et al. Blood Cancer Journal
- Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies
- (2021) Sudjit Luanpitpong et al. Journal of Immunology Research
- Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
- (2021) Veronika Bachanova et al. BLOOD
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
- (2021) Mark Yarmarkovich et al. NATURE
- Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
- (2021) Oliver Van Oekelen et al. NATURE MEDICINE
- Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells
- (2021) Jiao Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions
- (2021) Jeanette Wat et al. Journal of Allergy and Clinical Immunology-In Practice
- A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
- (2020) Chenggong Li et al. BLOOD
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
- (2020) Katharina Reinhard et al. SCIENCE
- Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
- (2020) Julia Hambach et al. Cells
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity
- (2020) Meisam Naeimi Kararoudi et al. BLOOD
- A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis
- (2020) Chengui Lu et al. MOLECULAR IMMUNOLOGY
- Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
- (2020) Meenakshi Hegde et al. Nature Communications
- Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
- (2020) Kitsada Wudhikarn et al. Blood Cancer Journal
- CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
- (2020) Alba Rodriguez-Garcia et al. Frontiers in Immunology
- Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
- (2020) Xiaomei Wang et al. Blood Advances
- Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
- (2020) Kevin R. Parker et al. CELL
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
- (2020) Nirav N. Shah et al. NATURE MEDICINE
- Exploring the NK cell platform for cancer immunotherapy
- (2020) Jacob A. Myers et al. Nature Reviews Clinical Oncology
- Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
- (2020) Hsiang-chi Tseng et al. Nature Communications
- Treatment of Multiple Myeloma using Chimeric Antigen Receptor T Cells with Dual Specificity
- (2020) Anat Globerson Levin et al. Cancer Immunology Research
- CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
- (2020) Mark Gurney et al. HAEMATOLOGICA
- Engineering Next-Generation CAR-T Cells for Better Toxicity Management
- (2020) Alain E. Andrea et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
- (2020) Xiang Zhou et al. Frontiers in Immunology
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
- (2019) Mohamad Hamieh et al. NATURE
- Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods
- (2019) Richard P. Harrison et al. CYTOTHERAPY
- Roles of NKT cells in cancer immunotherapy
- (2019) Eun-Ah Bae et al. ARCHIVES OF PHARMACAL RESEARCH
- Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers
- (2019) Andrew R. Haas et al. MOLECULAR THERAPY
- Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
- (2019) Daniela Pende et al. Frontiers in Immunology
- Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells
- (2019) Zhitao Gao et al. Journal of Genetics and Genomics
- Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
- (2019) Xiao Han et al. Journal of Hematology & Oncology
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts
- (2019) Yu Yang Ng et al. Molecular Therapy-Oncolytics
- Adoptive immunotherapy using PRAME-specific T cells in medulloblastoma
- (2018) Domenico Orlando et al. CANCER RESEARCH
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
- (2018) Matthew L Cooper et al. LEUKEMIA
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
- (2018) Julien Valton et al. Scientific Reports
- Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
- (2018) Shangjun Sun et al. Journal of Immunology Research
- Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
- (2018) Deepak Raj et al. GUT
- Emerging Cellular Therapies for Cancer
- (2018) Sonia Guedan et al. Annual Review of Immunology
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cellular therapies: the current landscape
- (2018) Maartje W. Rohaan et al. VIRCHOWS ARCHIV
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
- (2017) E Liu et al. LEUKEMIA
- Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers
- (2017) Chengcheng Zhang et al. MOLECULAR THERAPY
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Masked Chimeric Antigen Receptor for Tumor-Specific Activation
- (2017) Xiaolu Han et al. MOLECULAR THERAPY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- An oxygen sensitive self-decision making engineered CAR T-cell
- (2017) Alexandre Juillerat et al. Scientific Reports
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors
- (2016) Leonardo Morsut et al. CELL
- Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
- (2016) Kole T. Roybal et al. CELL
- Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers
- (2016) Qiong J. Wang et al. CLINICAL CANCER RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting natural killer cells in cancer immunotherapy
- (2016) Camille Guillerey et al. NATURE IMMUNOLOGY
- Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
- (2016) David T. Rodgers et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
- (2016) Rizwan Romee et al. Science Translational Medicine
- A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
- (2016) R. Sakemura et al. Cancer Immunology Research
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma
- (2015) Nadja Müller et al. JOURNAL OF IMMUNOTHERAPY
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
- (2015) M. J. Frigault et al. Cancer Immunology Research
- Identification of an ADAM17 Cleavage Region in Human CD16 (FcγRIII) and the Engineering of a Non-Cleavable Version of the Receptor in NK Cells
- (2015) Yawu Jing et al. PLoS One
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- The inducible caspase-9 suicide gene system as a “safety switch†to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
- (2014) Tessa Gargett et al. Frontiers in Pharmacology
- Cross-Talks between Natural Killer Cells and Distinct Subsets of Dendritic Cells
- (2014) Guido Ferlazzo et al. Frontiers in Immunology
- Are natural killer cells superior CAR drivers?
- (2014) Hans Klingemann OncoImmunology
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody
- (2013) Ge Zhang et al. IMMUNOLOGY AND CELL BIOLOGY
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Structural Analysis and Optimization of the Covalent Association between SpyCatcher and a Peptide Tag
- (2013) Long Li et al. JOURNAL OF MOLECULAR BIOLOGY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Microenvironmental regulation of tumor progression and metastasis
- (2013) Daniela F Quail et al. NATURE MEDICINE
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
- (2013) E. Lanitis et al. Cancer Immunology Research
- Cytokine activation induces human memory-like NK cells
- (2012) R. Romee et al. BLOOD
- Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
- (2012) K. Tamada et al. CLINICAL CANCER RESEARCH
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
- (2012) Scott Wilkie et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen
- (2012) B. Foley et al. JOURNAL OF IMMUNOLOGY
- A combined strategy improves the solubility of aggregation-prone single-chain variable fragment antibodies
- (2012) Wei Sun et al. PROTEIN EXPRESSION AND PURIFICATION
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- Epigenetic Memory and Preferential Lineage-Specific Differentiation in Induced Pluripotent Stem Cells Derived from Human Pancreatic Islet Beta Cells
- (2011) Ori Bar-Nur et al. Cell Stem Cell
- PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer
- (2011) A. L. Amir et al. CLINICAL CANCER RESEARCH
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Clinical Impact of Suicide Gene Therapy in Allogeneic Hematopoietic Stem Cell Transplantation
- (2010) Maria Teresa Lupo-Stanghellini et al. HUMAN GENE THERAPY
- Activating and inhibitory receptors of natural killer cells
- (2010) Hollie J Pegram et al. IMMUNOLOGY AND CELL BIOLOGY
- An Improved Bicistronic CD20/tCD34 Vector for Efficient Purification and In Vivo Depletion of Gene-Modified T Cells for Adoptive Immunotherapy
- (2010) Isabel Vogler et al. MOLECULAR THERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy
- (2010) Jan Spanholtz et al. PLoS One
- Adaptive immune features of natural killer cells
- (2009) Joseph C. Sun et al. NATURE
- Cytokine-induced memory-like natural killer cells
- (2009) Megan A. Cooper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy
- (2008) Nadia Guerra et al. IMMUNITY
- Up on the tightrope: natural killer cell activation and inhibition
- (2008) Lewis L Lanier NATURE IMMUNOLOGY
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
- A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer
- (2008) E. Kieback et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now